266 related articles for article (PubMed ID: 14556655)
1. Role of AML1/Runx1 in the pathogenesis of hematological malignancies.
Kurokawa M; Hirai H
Cancer Sci; 2003 Oct; 94(10):841-6. PubMed ID: 14556655
[TBL] [Abstract][Full Text] [Related]
2. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
[TBL] [Abstract][Full Text] [Related]
3. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies.
Zent C; Rowley JD; Nucifora G
Leukemia; 1997 Apr; 11 Suppl 3():273-8. PubMed ID: 9209363
[TBL] [Abstract][Full Text] [Related]
4. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
5. New mechanisms of AML1 gene alteration in hematological malignancies.
Roumier C; Fenaux P; Lafage M; Imbert M; Eclache V; Preudhomme C
Leukemia; 2003 Jan; 17(1):9-16. PubMed ID: 12529654
[TBL] [Abstract][Full Text] [Related]
6. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.
Tanaka K; Tanaka T; Kurokawa M; Imai Y; Ogawa S; Mitani K; Yazaki Y; Hirai H
Blood; 1998 Mar; 91(5):1688-99. PubMed ID: 9473235
[TBL] [Abstract][Full Text] [Related]
7. Runx1/AML1 in leukemia: disrupted association with diverse protein partners.
Perry C; Eldor A; Soreq H
Leuk Res; 2002 Mar; 26(3):221-8. PubMed ID: 11792409
[TBL] [Abstract][Full Text] [Related]
8. AML1 interconnected pathways of leukemogenesis.
Michaud J; Scott HS; Escher R
Cancer Invest; 2003; 21(1):105-36. PubMed ID: 12643014
[TBL] [Abstract][Full Text] [Related]
9. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice.
Cuenco GM; Ren R
Oncogene; 2004 Jan; 23(2):569-79. PubMed ID: 14724585
[TBL] [Abstract][Full Text] [Related]
10. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.
Osato M
Oncogene; 2004 May; 23(24):4284-96. PubMed ID: 15156185
[TBL] [Abstract][Full Text] [Related]
11. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1.
Sood R; Talwar-Trikha A; Chakrabarti SR; Nucifora G
Leukemia; 1999 Mar; 13(3):348-57. PubMed ID: 10086725
[TBL] [Abstract][Full Text] [Related]
12. Leukemogenesis by CBF oncoproteins.
Friedman AD
Leukemia; 1999 Dec; 13(12):1932-42. PubMed ID: 10602413
[TBL] [Abstract][Full Text] [Related]
13. Alterations of the AML1 transcription factor in human leukemia.
Downing JR; Higuchi M; Lenny N; Yeoh AE
Semin Cell Dev Biol; 2000 Oct; 11(5):347-60. PubMed ID: 11105899
[TBL] [Abstract][Full Text] [Related]
14. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations.
Nucifora G; Begy CR; Kobayashi H; Roulston D; Claxton D; Pedersen-Bjergaard J; Parganas E; Ihle JN; Rowley JD
Proc Natl Acad Sci U S A; 1994 Apr; 91(9):4004-8. PubMed ID: 8171026
[TBL] [Abstract][Full Text] [Related]
15. The role of the AML1 transcription factor in leukemogenesis.
Lorsbach RB; Downing JR
Int J Hematol; 2001 Oct; 74(3):258-65. PubMed ID: 11721960
[TBL] [Abstract][Full Text] [Related]
16. Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia.
Ganly P; Walker LC; Morris CM
Leuk Lymphoma; 2004 Jan; 45(1):1-10. PubMed ID: 15061191
[TBL] [Abstract][Full Text] [Related]
17. Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias.
Tanaka T; Mitani K; Kurokawa M; Ogawa S; Tanaka K; Nishida J; Yazaki Y; Shibata Y; Hirai H
Mol Cell Biol; 1995 May; 15(5):2383-92. PubMed ID: 7739522
[TBL] [Abstract][Full Text] [Related]
18. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family.
Fears S; Mathieu C; Zeleznik-Le N; Huang S; Rowley JD; Nucifora G
Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1642-7. PubMed ID: 8643684
[TBL] [Abstract][Full Text] [Related]
19. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis.
Yan M; Ahn EY; Hiebert SW; Zhang DE
Blood; 2009 Jan; 113(4):883-6. PubMed ID: 19036704
[TBL] [Abstract][Full Text] [Related]
20. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML.
Cuenco GM; Nucifora G; Ren R
Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1760-5. PubMed ID: 10677531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]